||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Amryt Pharma Share Discussion Threads
Showing 1001 to 1022 of 1025 messages
|The Shore Capital note is very positive as is their new target price of 88p for this "compelling investment opportunity ". Hopefully the market will agree and we will see the share price moving north in the coming weeks.|
|This share is in a pre-herd state.
When they arrive it may be too late imo|
|I'm hopeful the AMYT share price might double in the next few months. Fingers crossed!|
|There is a new research note from Shore Cap here:
Target price raised from 35p/share to 88p|
|Curnic1. Wild exagirated share price predictions are brokers bread and butter. The share price is at approx 18p so miles away from 88p and absolutely no interest from investors, big or small here.|
|Fro Shore Capital research note.
Amryt (AMYT)+ – Opportunity significantly de-risked; FV increased to 88p per share - House stock at 18.5p
Following the recent (6th March) update on the AP101 trial design and the positive newsflow during December (the €20m EIB loan and the licensing of EU/MENA rights to an approved ultra-rare disease product) we see the Amryt investment case as significantly de-risked. The €10m EIB financing tranche, available immediately, significantly reduces the near-term financing overhang, with Amryt now able to fund itself through to the pivotal Phase 3 EB data in mid-2018F. Together with the opportunity for near-term revenues from Lojuxta (lomitapide) in select countries, we see Amryt as a compelling investment opportunity, offering exposure to a promising late-stage clinical candidate (AP101 / Episalvan in EB) as well as a pipeline of early stage (AP102 in acromegaly) and marketed (Lojuxta in HoFH) products. With the additional financing flexibility from the EIB facility, together with the Lojuxta marketing agreement offering near-term revenues as well as the opportunity for Amryt to build its commercialisation infrastructure, we have lowered our discount rate to a still conservative 20% (from 30% previously), reflecting the clinical risk associated with EB. Together with our updated forecasts, to reflect the addition of Lojuxta, our revised DCF fundamental valuation is c. GBp 88/share, corresponding to an equity value of c.£180m.|
|Might see a bit of buying interest in AMYT in the lead up to next Thursday's RNS.|
|Just 4 trades so far today. 8181 shares in total. Around £1500. LOL.|
|I agree with post 900, there is plenty of bull round here|
|I'm going to copy, JP! YAWN!!!!! Only 3 small trades so far today. All sells. Total shares traded? A miserable 7466.
AMYT is just not on the radar of investors.|
|Shard Capital note:
|I think we may see a push up next week as we near the start of the phase 3 and the results. Whilst there's probably nothing material to report to 31 January 2016 that we don't already know, hopefully the Chairmans statement will hint of progress in 2017.|
|Cheer up, JP. At least AMYT is still listed. Think yourself lucky you don't have shares in either WRN or CTAG. You do have the option to sell your AMYT shares if you are unhappy with their performance (or are bored witless by them); WRN & CTAG shareholders don't have that option. Will they ever have that option again?
PS. At least AMYT have cash resources available to them; cash is something neither WRN or CTAG appear to have available to them.|
|For what it's worth hTTp://ichimokutrader.com/ has given 5 consecutive BULL signals for AMYT since the 1st March. 4 of those have been STRONG BULL signals. We shall see. Only time will tell. Fingers crossed!!|
|Consulting my tea leaves (charts) it's looking likely (to me at any rate) that the AMYT share price is poised to rise significantly in the short term. Since it's news that drives shareprices perhaps we are due some good news? Perhaps the coming results at the end of the month could trigger a re-rating of AMYT? Fingers crossed!!|
|Thanks for that, timbo003. Nothing we don't already know, but it does highlight the future investment potential of AMYT. I'm hopeful of a multi-bagger over the next few years, bwtfdik? AMYT have a very good, experienced, BoD, an EIB loan to cover trial costs and an interesting portfolio of orphan drugs that could turn out to be very profitable products in the future. You never know AMYT might even be the subject of a generous takeover bid. Fingers crossed!!!!!!!!!!!!!!!!!!!!|
|New research note out today from Shard Capital:
|Presenting at the proactive investor evening, lol. And what exactly are they going to present? Pictures of their new cars or perhaps some holiday snaps?|
|Amryt will be presenting at the Proactive investor evening on Thursday March 23rd, I plan to attend and will report back in due course:
|NY Boy 10 Mar '17 - 09:10 - 9105 of 9111 1 0
Hardly, more like buyers on the dips, investors weighing up what the share price will be at once they get long term cash by the end of the month,against the price now, so imho it's incredidly cheap here, even if it goes up another 200-400% before the month end.
Just sit back, reap the rewards Dyor
NY Boy 10 Mar '17 - 11:14 - 9108 of 9111 0 0
Kingston, sold out, looking to get in cheaper, nothing wrong with that. Any decent pull backs will be bought, because the real action to the upside hasn't commenced yet.
The above posts were by NY Boy this morning on the HER bb.
NY Boy? Ramper! FILTERED!|